ClinicalTrials.gg
Not yet recruitingNCT07848672Updated Sep 30, 2026

Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization

A Phase 2/3 interventional study of rhTPO prophylaxis plus EAP stem-cell mobilization in Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization and Chemotherapy-Induced Thrombocytopenia, sponsored by The Affiliated People's Hospital of Ningbo University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by The Affiliated People's Hospital of Ningbo University · Phase 2/3, Interventional, and Treatment

How we know

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, prospective, single-arm, phase II clinical study evaluating the early prophylactic use of recombinant human thrombopoietin (rhTPO) to prevent thrombocytopenia associated with the EAP regimen for hematopoietic stem cell mobilization. The EAP regimen consists of etoposide, cytarabine, and pegylated granulocyte colony-stimulating factor (pegfilgrastim) and is used for hematopoietic stem cell mobilization before autologous stem cell transplantation in patients with multiple myeloma and B-cell lymphoma.

Severe thrombocytopenia is a common complication during EAP-based stem cell mobilization and may increase the risk of bleeding and the need for platelet transfusions, and may sometimes delay stem cell collection. In this study, patients whose platelet counts decrease to ≤80 × 10⁹/L after EAP chemotherapy will receive rhTPO early as a preventive treatment. The study will evaluate whether early rhTPO administration can reduce the incidence of clinically significant bleeding and the need for platelet transfusion while maintaining adequate hematopoietic stem cell mobilization.

The study will also monitor platelet counts, stem cell collection outcomes, and treatment-related adverse events to evaluate the effectiveness and safety of early rhTPO administration.

02

Conditions studied

  • Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
  • Hematopoietic Stem Cell Mobilization
  • Chemotherapy-Induced Thrombocytopenia
03

In context

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

This study's planned enrollment of 70 is above the median of 41 across 3,009 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

The Affiliated People's Hospital of Ningbo University is the lead sponsor of 11 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 75 years old.
  2. Confirmed diagnosis of multiple myeloma or B-cell lymphoma, eligible for hematopoietic stem-cell transplantation and planned to receive EAP-based stem-cell mobilization.
  3. Baseline peripheral count ≥ 80 × 10⁹/L.
  4. Adequate cardiac, hepatic and renal function to tolerate EAP-combination chemotherapy.
  5. Willing and able to complete the full-study follow-up procedures.
  6. Voluntarily provide written .

Exclusion criteria

Exclusion Criteria:

  1. Previous history of arterial or venous thromboembolism including pulmonary embolism.
  2. Liver cirrhosis or baseline (ALT) > 2 times .
  3. Active uncontrolled infection.
  4. Confirmed myelofibrosis.
  5. Pregnant or lactating female subjects.
  6. Known to recombinant human thrombopoietin (rhTPO).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Prophylactic early-use rhTPO for chemotherapy-induced thrombocytopenia during EAP-based hematopoieti

    This is the only interventional arm of this multicenter, prospective, single-arm phase II study. Eligible patients with lymphoma or multiple myeloma receive standard EAP mobilization chemotherapy (etoposide 75 mg/m² i.v. d1-2, cytarabine 200 mg/m² q12h i.v. d1-2; pegfilgrastim is administered subcutaneously on day 6 after completion of chemotherapy; dose reduction to 2/3-3/4 of original dose is allowed for patients \> 65 years or creatinine clearance 30-60 mL/min). After EAP chemotherapy, blood routine tests are monitored dynamically. When peripheral platelet count drops to ≤ 80 × 10⁹/L, \*\*prophylactic recombinant human thrombopoietin (rhTPO) 300 U/kg is given subcutaneously once daily\*\*. rhTPO administration continues until completion of stem-cell apheresis, platelet recovery \> 50 × 10⁹/L, or investigator-judged discontinuation. Platelet transfusion is only permitted when platelet count \< 20 × 10⁹/L or active bleeding occurs. Subjects undergo serial laboratory assessments including

    Drug: rhTPO prophylaxis plus EAP stem-cell mobilization

Interventions

  • DrugrhTPO prophylaxis plus EAP stem-cell mobilization

    Standard EAP mobilization chemotherapy (etoposide + cytarabine + pegfilgrastim) plus early prophylactic subcutaneous rhTPO 300 U/kg/day initiated when platelet ≤80 ×10⁹/L. rhTPO stops after stem-cell collection, platelet recovery \>50 ×10⁹/L or investigator's decision. Platelet transfusion follows unified trigger criteria: PLT\<20×10⁹/L or active bleeding.

06

What researchers measure

Primary outcomes

  1. Platelet transfusion rate during mobilization period

    Proportion of participants receiving at least one platelet transfusion in the mobilization phase.

    Time frame: From initiation of EAP chemotherapy to completion of the last stem-cell apheresis,assessed up to 30 days.

  2. Incidence of grade ≥2 bleeding events during mobilization period

    Proportion of participants experiencing CTCAE v5.0 grade ≥2 bleeding events throughout the stem-cell mobilization cycle.

    Time frame: From initiation of EAP chemotherapy to completion of the last stem-cell apheresis,assessed up to 40 days.

Secondary outcomes

  1. Nadir platelet count

    The minimum peripheral platelet count observed in mobilization cycle.

    Time frame: From initiation of EAP chemotherapy to completion of the last stem-cell apheresis, assessed up to 40 days.

  2. Duration of platelet count <20 ×10⁹/L

    Number of days with platelet count below 20 ×10⁹/L.

    Time frame: From initiation of EAP chemotherapy to completion of the last stem-cell apheresis,assessed up to 40 days.

  3. Proportion of participants with delayed stem-cell apheresis due to severe thrombocytopenia

    Percentage of subjects whose apheresis is postponed because of severe thrombocytopenia.

    Time frame: From initiation of EAP chemotherapy to completion of the last stem-cell apheresis,assessed up to 30 days.

  4. Stem-cell mobilization success rate

    Proportion of participants achieving total CD34⁺ cell yield ≥5 ×10⁶/kg body weight.

    Time frame: At completion of stem-cell apheresis,assessed up to 30 days.

  5. Incidence of adverse events

    Incidence of thromboembolism, liver injury, severe bone pain, severe infection graded by CTCAE v5.0.

    Time frame: From start of study intervention to completion of stem-cell collection, assessed up to 40 days.

  6. Length of hospital stay during mobilization

    Total hospital days in the mobilization stage.

    Time frame: From admission for EAP mobilization to discharge after apheresis finished,assessed up to 30 days.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Sep 30, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 1, 2030
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848672
Lead sponsor
The Affiliated People's Hospital of Ningbo University
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Sep 30, 2026

Study contacts

Yuxiao Wang
Contact
799161574@qq.com
13486889847

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion